Anandhakrishnan A, Korbonits M. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J Diabetes 2016; 7(20): 572-598 [PMID: 28031776 DOI: 10.4239/wjd.v7.i20.572]
Corresponding Author of This Article
Márta Korbonits, Professor of Endocrinology and Metabolism, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6 BQ, United Kingdom. m.korbonits@qmul.ac.uk
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Dec 15, 2016; 7(20): 572-598 Published online Dec 15, 2016. doi: 10.4239/wjd.v7.i20.572
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Ananthi Anandhakrishnan, Márta Korbonits
Ananthi Anandhakrishnan, Márta Korbonits, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6 BQ, United Kingdom
Author contributions: Anandhakrishnan A wrote the paper; Korbonits M had original idea and reviewed the paper.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Márta Korbonits, Professor of Endocrinology and Metabolism, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6 BQ, United Kingdom. m.korbonits@qmul.ac.uk
Telephone: +44-20-78826238 Fax: +44-20-78826197
Received: June 14, 2016 Peer-review started: June 27, 2016 First decision: July 27, 2016 Revised: September 27, 2016 Accepted: October 17, 2016 Article in press: October 18, 2016 Published online: December 15, 2016 Processing time: 178 Days and 3.2 Hours
Core Tip
Core tip: Several lines of clinical evidence implicate an important functional role for glucagon-like peptide 1 (GLP-1) signalling in the pathophysiology of clinical obesity. Here we critically evaluate such findings in way that as yet has been unexplored; using the well established roles of GLP-1 as an incretin and meal to meal satiety signal to go some way toward explaining findings from interventional and observational clinical data that suggest functional deficits of GLP-1 to be a contributor to the obesity phenotype. We also explore the promise shown by GLP-1 analogues in achieving and maintaining significant weight loss in obese individuals, and use findings to discuss to what extent they too may support a role for GLP-1 in obesity pathophysiology. We conclude by exploring what an association with functional GLP-1 deficit could mean for the clinical management of obesity; conducting cost and risk benefit analyses to evaluate the extent to which GLP-1 analogues may provide a successful and sustainable option for the medical management of obesity that remains as yet, an unmet clinical need.
